Maquet launches trial to assess OPTIONs of EVH vs. CABG

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The first patient has been enrolled into the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) trial, that will compare endoscopic vessel harvesting (EVH) for CABG with open vein harvesting approaches.

The trial, which is expected to enroll 100 patients, will use Maquet Cardiovascular's Vasoview Hemopro 2 system and assess vein graft patency at one-month and one-year post-CABG surgery.

According to the company, the EVH offers a less invasvie approach to CABG surgery in comparison with open vein harvesting, which requires a larger incision that often initiates patient discomfort and is more prone to complications.

Maquet said that the trial will standardize pre- and post-harvesting factors including using controlled pressure during conduit preparation via the Vasoshield Pressure Controlling Syringe.

The study is being conducted by principal investigator David Moore, MD, of the Heart Hospital Baylor Plano in Plano, Texas, and the first patient was enrolled at the Medical City Dallas Hospital in Dallas. The first patient, a 65-year-old-male, received four grafts with two arteries and two grafts using saphenous veins harvested via the Vasoview system.

According to the company, 80 percent of the CABG procedures conducted in the U.S. use EVH.